Joseph Kiani - Stereotaxis Director
| STXS Stock | USD 2.30 0.05 2.13% |
Director
Mr. Joseph E. Kiani is Independent Director of the Company. He is the founder, Chairman of the board of directors, and CEO of Masimo, a global medical technology innovator. He was a beacon for patient safety and innovation in healthcare for more than 25 years. He founded Masimo in 1989 to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. Under his leadership, Masimo has grown from a garage start up into a successful publicly traded company employing more than 3, 500 people. Masimo has helped to solve the unsolvable problems plaguing patient monitoring through significant inventions with more than 600 issued and pending patents worldwide. From 1997 to 2013, Mr. Kiani served on the board of directors of Saba Software, Inc., a publicly traded software company focused on human capital development and management solutions. Committed to patient safety, Mr. Kiani founded the Patient Safety Movement Foundation in 2012 and the World Patient Safety, Science Technology Summit. The Patient Safety Movement Foundation has the goal of eliminating preventable deaths by 2020 in the US, and significantly reducing preventable deaths in hospitals worldwide. Today, PSMF has over 3, 500 hospitals from around the world that have committed to patient safety. In January 2016, the hospitals that had joined Patient Safety Movement reported 24, 643 lives saved annually. Mr. Kianis deep understanding of the healthcare industry as well as his broad experience in strategic planning, strategic innovations, engineering and product innovation are valuable in supporting and guiding our product development, growth, technology innovation and operational excellence. since 2016.
| Age | 52 |
| Tenure | 8 years |
| Phone | 314 678 6100 |
| Web | https://www.stereotaxis.com |
Stereotaxis Management Efficiency
The company has return on total asset (ROA) of (0.2864) % which means that it has lost $0.2864 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7693) %, meaning that it created substantial loss on money invested by shareholders. Stereotaxis' management efficiency ratios could be used to measure how well Stereotaxis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jack Goldstein | Accuray Incorporated | 70 | |
| Joseph Whitters | Cutera Inc | 60 | |
| Elizabeth Krell | AtriCure | 67 | |
| Jeffrey Gold | AngioDynamics | 69 | |
| Robrecht Michiels | EDAP TMS SA | N/A | |
| Beverly Huss | Accuray Incorporated | 57 | |
| Kristine Johnson | AtriCure | 66 | |
| Argil Wheelock | EDAP TMS SA | 66 | |
| Jan Reed | AngioDynamics | 58 | |
| Richard Pettingill | Accuray Incorporated | 69 | |
| Pierre Beysson | EDAP TMS SA | N/A | |
| Katherine Zanotti | Cutera Inc | 63 | |
| Mark Collar | AtriCure | 65 | |
| Karen Robards | AtriCure | 67 | |
| Michael Hooven | AtriCure | 60 | |
| Jerry Widman | Cutera Inc | 71 | |
| Gregory Barrett | Cutera Inc | 64 | |
| Sriram Venkataraman | AngioDynamics | 42 | |
| Emad Rizk | Accuray Incorporated | 52 | |
| Dennis Winger | Accuray Incorporated | 68 | |
| Joseph Whitters | Accuray Incorporated | 60 | |
Management Performance
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.29 |
Stereotaxis Leadership Team
Elected by the shareholders, the Stereotaxis' board of directors comprises two types of representatives: Stereotaxis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stereotaxis. The board's role is to monitor Stereotaxis' management team and ensure that shareholders' interests are well served. Stereotaxis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stereotaxis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Duane DeSisto, Director | ||
| Ross Levin, Director | ||
| Paul Brathwaite, Vice President - Research & Development | ||
| Laura Garth, General Secretary | ||
| Arun Menawat, Director | ||
| CAIA CFA, CEO Chairman | ||
| Joseph Keegan, Independent Director | ||
| John Platt, Director Software | ||
| Joseph Kiani, Director | ||
| Fred Middleton, Independent Director | ||
| Keith Galloway, Vice Operations | ||
| Guy Judkowski, Equity Manager | ||
| David Fischel, Director | ||
| Brian Kidd, RD Devel | ||
| Euan Thomson, Independent Director | ||
| Eric Prystowsky, Independent Director | ||
| Karen Duros, Sr. VP, General Counsel and Secretary | ||
| Frank Cheng, Sr. VP of Marketing and Bus. Devel. | ||
| Susan Lanigan, Executive Vice President General Counsel | ||
| David Giffin, VP of HR | ||
| Martin Stammer, CFO and Principal Accounting Officer | ||
| Nathan Kastelein, RD Concepts | ||
| Robert Messey, Independent Director | ||
| William Mills, Chairman of the Board, CEO | ||
| Nathan Fischel, Director | ||
| David Benfer, Independent Director | ||
| Kimberly Peery, CFO Secretary |
Stereotaxis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stereotaxis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (1.16) % | ||||
| Current Valuation | 180.14 M | ||||
| Shares Outstanding | 82.13 M | ||||
| Shares Owned By Insiders | 15.87 % | ||||
| Shares Owned By Institutions | 47.49 % | ||||
| Number Of Shares Shorted | 930.89 K | ||||
| Price To Earning | 21.61 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stereotaxis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stereotaxis' short interest history, or implied volatility extrapolated from Stereotaxis options trading.
Currently Active Assets on Macroaxis
When determining whether Stereotaxis is a strong investment it is important to analyze Stereotaxis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Stereotaxis' future performance. For an informed investment choice regarding Stereotaxis Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stereotaxis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Stereotaxis Stock please use our How to Invest in Stereotaxis guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Stereotaxis Stock analysis
When running Stereotaxis' price analysis, check to measure Stereotaxis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stereotaxis is operating at the current time. Most of Stereotaxis' value examination focuses on studying past and present price action to predict the probability of Stereotaxis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stereotaxis' price. Additionally, you may evaluate how the addition of Stereotaxis to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Stereotaxis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stereotaxis. If investors know Stereotaxis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stereotaxis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Stereotaxis is measured differently than its book value, which is the value of Stereotaxis that is recorded on the company's balance sheet. Investors also form their own opinion of Stereotaxis' value that differs from its market value or its book value, called intrinsic value, which is Stereotaxis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stereotaxis' market value can be influenced by many factors that don't directly affect Stereotaxis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stereotaxis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stereotaxis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stereotaxis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.